দেশ: যুক্তরাজ্য
ভাষা: ইংরেজি
সূত্র: MHRA (Medicines & Healthcare Products Regulatory Agency)
Ranitidine hydrochloride
Omega Pharma Ltd
A02BA02
Ranitidine hydrochloride
75mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01030100; GTIN: 5000347079122 5000347079160
70 11 9 11 11 9 11 70 9 MANUFACTURED BY: Glaxo Wellcome SA, Aranda de Duero, Burgos, Spain or Omega Pharma International, Venecoweg 26, B-9810 Nazareth, Belgium. or Famar Italia S.p.A, Via Zambeletti, 25 20021 - Baranzate (MI) ITALY This leaflet was revised in March 2016. REPORTING OF SIDE EFFECTS: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects, you can help provide more information on the safety of this medicine. Store below 25˚C. Tablets should not be removed from blisters until immediately prior to use. Keep out of the reach and sight of children. DO NOT USE THIS MEDICINE AFTER THE ‘EXP’ DATE SHOWN ON THE PACK. Talk to your doctor or pharmacist before taking Zantac 75 Relief if you are taking any other medicines, including those obtained without a prescription; particularly MEDICINES TO PREVENT BLOOD CLOTTING, such as WARFARIN, medicines for insomnia (e.g. triazolam, midazolam), medicines for lowering blood glucose (e.g. glipizide), medicines for fungal infections (e.g. ketoconazole, itraconazole, posaconazole), medicines for treating HIV infection (e.g. atazanavir, delavirdine), medicines for lung cancer (e.g. gefitnib) and NON-STEROIDAL ANTI-INFLAMMATORY PAINKILLERS (e.g. ASPIRIN or IBUPROFEN). This advice is even more important if you are elderly. LF03526E 2623602 / IS-150-152-60B2 25 File title: 9773_LF03526E_2623602_ZANTAC RELIEF 75 6S-12S LEAFLET_UK V6 Item No.: 2623602 OPI No.: LF03526E Replacement No.: ... Last edit: 28th April 2016 Brand: ZANTAC Variant: Relief 75 mg tablets Component: Leaflet Market/s: UK Dimensions: 152 x 150 mm CG283_IS-150-152-60B2 Reel Unwind: ... Spec. Ref.: ... Substrate: White Paper PharmaCode: 25 EAN Code: N/A Other Code/Spec.: ... Manufacturing Site: FAMAR IT Printer: ... No. of Colours: 1 Process Black Cutter সম্পূর্ণ নথি পড়ুন
OBJECT 1 ZANTAC 75 RELIEF Summary of Product Characteristics Updated 08-Jul-2016 | Omega Pharma Ltd 1. Name of the medicinal product Zantac 75 Relief 2. Qualitative and quantitative composition Quantities per tablet Active Ingredient: Ranitidine Hydrochloride 84mg (equivalent to ranitidine 75mg) 3. Pharmaceutical form Tablet 4. Clinical particulars 4.1 Therapeutic indications Symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity. 4.2 Posology and method of administration Route of Administration Oral Dosage Adults (Including the elderly) and children 16 years of age and older: Swallow one Zantac 75 Relief tablet whole, with a drink of water, as soon as you have symptoms. If symptoms persist for more than one hour or return, take another tablet. Do not take more than two tablets in 24 hours. Do not take the tablets for more than 6 days without the advice of a pharmacist or doctor. Children under 16 years Not recommended for children under 16 years of age. 4.3 Contraindications Ranitidine is contraindicated for people known to be hypersensitive to the drug or any of the ingredients of Zantac 75 Relief tablets. 4.4 Special warnings and precautions for use Treatment with a histamine H 2 -antagonist such as Zantac 75 Relief may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with renal impairment (creatinine clearance less than 50 ml/min). Zantac 75 Relief is not suitable for these patients without medical supervision. People taking non-steroidal anti-inflammatory drugs, especially those with a history of peptic ulcer and the elderly, should not self-medicate with Zantac 75 Relief but seek their doctor's advice before use. People with a history of porphyria should avoid use of the product. Consumers will be advised not to purchase a second pack of tablets without the advice of a pharmacist of doctor. The product is not indicated in the foll সম্পূর্ণ নথি পড়ুন